|Title||Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Rossman, MJ, Santos-Parker, JR, Steward, CAC, Bispham, NZ, Cuevas, LM, Rosenberg, HL, Woodward, KA, Chonchol, M, Gioscia-Ryan, RA, Murphy, MP, Seals, DR|
|Date Published||2018 Apr 16|
Excess reactive oxygen species production by mitochondria is a key mechanism of age-related vascular dysfunction. Our laboratory has shown that supplementation with the mitochondrial-targeted antioxidant MitoQ improves vascular endothelial function by reducing mitochondrial reactive oxygen species and ameliorates arterial stiffening in old mice, but the effects in humans are unknown. Here, we sought to translate our preclinical findings to humans and determine the safety and efficacy of MitoQ. Twenty healthy older adults (60-79 years) with impaired endothelial function (brachial artery flow-mediated dilation 7.60 m/s; n=11). Plasma oxidized LDL (low-density lipoprotein), a marker of oxidative stress, also was lower after MitoQ versus placebo (0.1). These findings in humans extend earlier preclinical observations and suggest that MitoQ and other therapeutic strategies targeting mitochondrial reactive oxygen species may hold promise for treating age-related vascular dysfunction.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02597023.
|Grant List||F32 AG053009 / AG / NIA NIH HHS / United States |
R21 AG049451 / AG / NIA NIH HHS / United States
T32 AG000279 / AG / NIA NIH HHS / United States
UL1 TR001082 / TR / NCATS NIH HHS / United States